Leidos Holdings (NYSE: LDOS) stock fell sharply on Tuesday, reaching a fresh 52-week low and extending its year-to-date decline past 31%, after Jefferies downgraded the defense technology company and cut its price target by more than $40, citing structural headwinds facing the company's health business.

Jefferies moved its rating on LDOS stock to Hold from a more constructive prior stance and slashed its price objective to $140 from $185. The analyst cited two primary concerns: profit margin sustainability across Leidos's defense contracts amid U.S. government spending uncertainty, and a specific risk tied to the Defense Health Agency, which is reportedly planning to move away from the lead-integrator contracting model.

The DHA structural shift matters because Leidos has built a meaningful portion of its health segment revenue around the role of lead integrator, managing complex healthcare IT systems on behalf of the Department of Defense. If the agency transitions to a more fragmented multi-vendor approach, Leidos would need to compete for smaller individual contracts rather than managing a consolidated program, a shift that typically compresses both revenue scale and margins.

The LDOS stock decline contrasted sharply with the broader market. The Information Technology sector gained close to 2% on Tuesday while the S&P 500 advanced approximately 1.5%, both driven by expectations that the U.S.-Iran peace deal would ease inflationary pressure and support risk assets. Leidos's inability to participate in that rally, let alone its sharp reversal, underscores the degree to which analyst-driven sector concerns can override macro tailwinds.

This is particularly striking because Leidos's underlying fundamental performance has been solid. The company beat first-quarter 2026 estimates and raised its full-year earnings per share guidance to a range of $12.10 to $12.50, a creditable operational execution story.

For investors in defense stocks or government technology services companies in 2026, Leidos stock represents a case where strong execution is insufficient to overcome concerns about structural changes in the contract framework of a key customer.

Key Highlights

  • Jefferies downgraded Leidos Holdings to Hold and cut its price target to $140 from $185, a reduction of more than 24%, citing concerns about profit margin sustainability and the Defense Health Agency's reported plans to move away from the lead-integrator contracting model.
  • Leidos stock has now declined more than 31% year-to-date and hit a fresh 52-week low on Tuesday, sharply contrasting with a near-2% gain in the broader Information Technology sector and a roughly 1.5% advance in the S&P 500.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.